her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Published 1 year ago • 1.4K plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
1:22
her2dx risk-score in early-stage her2-positive breast cancer
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
1:38
compassher2-pcr: de-escalation of neoadjuvant chemotherapy for breast cancer
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
3:49
her2dx: a new diagnostic tool for early-stage her2 positive breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
4:50
overview of neoadjuvant therapy in her2 breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
0:45
dr. hamilton on using pcr to classify risk in her2 breast cancer
-
2:05
adding nivolumab to neoadjuvant chemo improves response rate for high risk er her2− breast cancer
-
4:46
ea1181/compassher2 pcr research study for her2-positive breast cancer - full video
-
4:52
3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
0:47
dr. yee on neoadjuvant pertuzumab in her2-positive breast cancer